Yesterday I wrote about perifisone. This exciting new anti-cancer compound is being tested on several types of cancer in addition to multiple myeloma. Here is another example of a new crossover cancer drug. INK128 is a novel, orally available small molecule inhibitor of the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway, and it has also shown promising anti-tumor activity in preclinical models of multiple myeloma. It is already being studies for a number of solid tumor applications. In an attempt to kick-start multiple myeloma research using the drug, the Multiple Myeloma Research Foundation (“MMRF”) awarded a grant of up to one million dollars to support clinical development of INK128 in patients with multiple myeloma.
The manufacturer, Intellikine, is a venture-backed company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine anticipates initiating a Phase I clinical trial in patients with multiple myeloma in the second-half of 2010.
Here is a link to information about the upcomming Phase I trial, which is just starting to fill 56 patient openings this month: Dose Escalation Study of INK128 in Relapsed or Refractory Multiple Myeloma.
Phase I studies are unlikely to help participating patients directly–but we all have to start somewhere. Still, there have been a number of cases from other studies in the past where patients did see an improvement in their numbers while participating in a Phase I trial of anti-myeloma combounds.
Feel good and keep smiling! Pat